{"id":25248,"date":"2025-06-11T15:41:41","date_gmt":"2025-06-11T08:41:41","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=25248"},"modified":"2025-06-11T15:41:41","modified_gmt":"2025-06-11T08:41:41","slug":"energenesis-biomedical-to-unveil-promising-parkinsons-disease-therapy-energi-f705pd-at-bio-international-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=25248","title":{"rendered":"Energenesis Biomedical to Unveil Promising Parkinson&#8217;s Disease Therapy, ENERGI-F705PD, at BIO International 2025"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 11, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place <b>June 16\u201319 in <span class=\"xn-location\">Boston, MA<\/span><\/b>. The company will be located at <b>Booth #1645 within the Taiwan Pavilion<\/b>, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson&#8217;s disease (PD) therapy, <b>ENERGI-F705PD<\/b>, a first-in-class treatment with disease-modifying potential.<\/p>\n<p><b>Key Highlights:<\/b><\/p>\n<ul type=\"disc\">\n<li>ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson&#8217;s disease, designed to address the underlying pathogenesis.<\/li>\n<li>Topline data from the Phase I trial in healthy subjects are anticipated in <span class=\"xn-chron\">September 2025<\/span>, following successful completion of recruitment.<\/li>\n<li>ENERGI-F705PD aims to combat the root causes of Parkinson&#8217;s by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis.<\/li>\n<\/ul>\n<p>&#8220;We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025,&#8221; said\u00a0<b><span>Dr. <span class=\"xn-person\">Han-Min Chen<\/span>, CEO of Energenesis Biomedical<\/span><\/b>. &#8220;Parkinson&#8217;s disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy.&#8221;<\/p>\n<p><b>About ENERGI-F705PD<\/b><\/p>\n<p>ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson&#8217;s disease:<\/p>\n<ul type=\"disc\">\n<li><b>Reduce and Prevent \u03b1-Synuclein Aggregation:<\/b> Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded \u03b1-synuclein, a central pathogenic hallmark of PD.<\/li>\n<li><b>Increase Reducing Power (antioxidant):<\/b> ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense.<\/li>\n<li><b>Increase Tyrosine Hydroxylase Expression\/activity:<\/b> By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients.<\/li>\n<\/ul>\n<p><b>About\u00a0Energenesis Biomedical<\/b><\/p>\n<p>Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders.<\/p>\n<p>The company&#8217;s robust pipeline includes:<\/p>\n<ul type=\"disc\">\n<li><b><span>ENERGI-F705PD:<\/span><\/b><span>\u00a0Oral tablet for Parkinson&#8217;s disease (Phase I)<\/span><\/li>\n<li><b><span>ENERGI-F703DFU:<\/span><\/b><span>\u00a0Gel for Diabetic\u00a0foot ulcers (Phase III)<\/span><\/li>\n<li><b><span>ENERGI-F701:<\/span><\/b><span>\u00a0Tonic for Alopecia\u00a0(Phase II completed)<\/span><\/li>\n<li><b><span>ENERGI-F703EB:<\/span><\/b><span> Cream for\u00a0Epidermolysis\u00a0bullosa\u00a0(EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA\u00a0orphan designation(Preparing for Phase II)<\/span><\/li>\n<\/ul>\n<p>For more information, please visit <a href=\"http:\/\/www.energenesis-biomedical.com\/en\" target=\"_blank\" rel=\"nofollow\">www.energenesis-biomedical.com\/en<\/a><\/p>\n<p><b>Contact:<\/b> Business Development Team<\/p>\n<p>Email: <a href=\"mailto:partnership@energenesis-biomedical.com\" target=\"_blank\" rel=\"nofollow\">partnership@energenesis-biomedical.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 11, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place <b>June 16\u201319 in <span class=\"xn-location\">Boston, MA<\/span><\/b>. The company will be located at <b>Booth #1645 within the Taiwan Pavilion<\/b>, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson&#8217;s disease (PD) therapy, <b>ENERGI-F705PD<\/b>, a first-in-class treatment with disease-modifying potential.<\/p>\n<p><b>Key Highlights:<\/b><\/p>\n<ul type=\"disc\">\n<li>ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson&#8217;s disease, designed to address the underlying pathogenesis.<\/li>\n<li>Topline data from the Phase I trial in healthy subjects are anticipated in <span class=\"xn-chron\">September 2025<\/span>, following successful completion of recruitment.<\/li>\n<li>ENERGI-F705PD aims to combat the root causes of Parkinson&#8217;s by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis.<\/li>\n<\/ul>\n<p>&#8220;We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025,&#8221; said\u00a0<b><span>Dr. <span class=\"xn-person\">Han-Min Chen<\/span>, CEO of Energenesis Biomedical<\/span><\/b>. &#8220;Parkinson&#8217;s disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy.&#8221;<\/p>\n<p><b>About ENERGI-F705PD<\/b><\/p>\n<p>ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson&#8217;s disease:<\/p>\n<ul type=\"disc\">\n<li><b>Reduce and Prevent \u03b1-Synuclein Aggregation:<\/b> Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded \u03b1-synuclein, a central pathogenic hallmark of PD.<\/li>\n<li><b>Increase Reducing Power (antioxidant):<\/b> ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense.<\/li>\n<li><b>Increase Tyrosine Hydroxylase Expression\/activity:<\/b> By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients.<\/li>\n<\/ul>\n<p><b>About\u00a0Energenesis Biomedical<\/b><\/p>\n<p>Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders.<\/p>\n<p>The company&#8217;s robust pipeline includes:<\/p>\n<ul type=\"disc\">\n<li><b><span>ENERGI-F705PD:<\/span><\/b><span>\u00a0Oral tablet for Parkinson&#8217;s disease (Phase I)<\/span><\/li>\n<li><b><span>ENERGI-F703DFU:<\/span><\/b><span>\u00a0Gel for Diabetic\u00a0foot ulcers (Phase III)<\/span><\/li>\n<li><b><span>ENERGI-F701:<\/span><\/b><span>\u00a0Tonic for Alopecia\u00a0(Phase II completed)<\/span><\/li>\n<li><b><span>ENERGI-F703EB:<\/span><\/b><span> Cream for\u00a0Epidermolysis\u00a0bullosa\u00a0(EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA\u00a0orphan designation(Preparing for Phase II)<\/span><\/li>\n<\/ul>\n<p>For more information, please visit <a href=\"http:\/\/www.energenesis-biomedical.com\/en\" target=\"_blank\" rel=\"nofollow\">www.energenesis-biomedical.com\/en<\/a><\/p>\n<p><b>Contact:<\/b> Business Development Team<\/p>\n<p>Email: <a href=\"mailto:partnership@energenesis-biomedical.com\" target=\"_blank\" rel=\"nofollow\">partnership@energenesis-biomedical.com<\/a><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-25248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25248"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/25248\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}